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Novel ruthenium(III) complexes with histamine [RuCl4(dmso-S)(histamineH)]·H2O( 1a) and [RuCl4(dmso-S)(histamineH)]
(1b) have been prepared and characterized by X-ray structure analysis. Their crystal structures are similar and show a protonated
amino group on the side chain of the ligand which is not very common for a simple heterocyclic derivative such as histamine.
Biological assays to test the cytotoxicity of the compound 1b combined with electroporation were performed to determine its
potential for future medical applications in cancer treatment.
1.Introduction
Before the discovery of cisplatin and its successful use as
an anticancer agent in the 70s, metal complexes were rarely
considered useful for medical applications. Afterwards, new
cisplatin analogues (carboplatin, oxaliplatin) were developed
and introduced into clinical use [1–3]. The development
of platinum-drug resistance in cancer patients, the general
toxicity and severe side eﬀects of platinum drugs however
required a diﬀerent approach in the research of anticancer
metal complexes [2].
Complexes of diﬀerent metals were prepared and tested.
Two ruthenium compounds, NAMI-A and KP1019 [4–6],
are currently among the most successful candidates to enter
the clinical practice. These two ruthenium(III) complexes
have an octahedral geometry and contain four in-plane
chlorido ligands as well as one dimethylsulfoxido and one
imidazolo (NAMI-A) or two indazolo ligands (KP1019) in
trans positions. The aforementioned compounds are the
chosen representatives of two larger classes of compounds
bearing nitrogen-bound aromatic heterocycles developed
by the Alessio and Keppler research groups, respectively
[4, 7, 8].
Histamine (4-(2-Aminoethyl)-1H-imidazole, seeScheme
2) is a molecule that performs various functions in the body,
the most important being the gastric acid secretion and
the triggering of the symptoms of an allergic reaction such
as vasodilatation, bronchoconstriction, bronchial muscle
contraction, pain, and itching.
Most of the metal complexes in use in current cancer
treatment have an intracellular target and the plasma mem-
brane can represent a considerable barrier. Electroporation
or electropermeabilization is a process where exposing cells
to speciﬁc electrical pulses results in temporary formation
of hydrophilic pores in the cell membrane. Thus temporally
increased cell permeability enables extracellular molecules
with otherwise hampered transmembrane transport to enter
the cells. Electroporation is used in a variety of biotechno-
logical and medical applications. It has been proven that
combining electroporation with chemotherapy potentiates
the cytotoxicity of drugs when the drugs’ eﬃcacy is limited
b yi t su p t a k ei nt h ec e l l[ 9–13].
The aim of this study was to prepare and characterize
new ruthenium NAMI-type compounds, to test their in vitro
cytotoxicityandstudytheinﬂuenceofelectroporationonthe
cytotoxic activity of the synthesized compounds.2 Bioinorganic Chemistry and Applications
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Scheme 3: Two step synthesis and structure of the novel ruthenium
complex with histamine.
2. Experimental
2.1. Materials and Instruments. Ruthenium(III) chloride
hydrate, histamine dihydrochloride, and the solvents
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Figure 1: Asymmetric unit of the crystal structure of complex 1b.
The ellipsoids are shown at 50% probability.
(dimethylsulfoxide, concentrated hydrochloric acid, metha-
nol, ethanol, and acetone) were purchased by Sigma-Aldrich
and used without further puriﬁcation.
2.1.1. Infrared Spectroscopy. Infrared spectra (ATR) were
recorded on a Perkin-Elmer Spectrum 100 spectrometer.
The measurements were made in the range from 4000 to
600cm−1.
2.1.2. Electrospray Ionization Mass Spectrometry. Mass mea-
surements were run on a hybrid quadrupole time of ﬂight
mass spectrometer Q-Tof Premier (Waters Micromass,
Manchester, UK), equipped with an orthogonal Z-spray
electrospray (ESI) interface.
Water sample solution was introduced directly through
s y r i n g ep u m pa taﬂ o wr a t e5μL/min. Compressed nitrogenBioinorganic Chemistry and Applications 3
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Figure 2:Thehydrogenbondsinthecrystalstructureofcompound
1b. The ammonioethyl groups of the lower two asymmetric units
are omitted for clarity.
(99.999%, Messer Slovenia) was used as both the drying
and the nebulizing gas. The nebulizer gas ﬂow rate was set
to approximately 20L/h and the desolvation gas ﬂow rate
to 600L/h. A cone voltage of 30V and a capillary voltage
of 2.9kV were used in positive ion mode. The desolvation
temperature was set to 150
◦C and the source temperature to
100
◦C.Themassresolutionofapproximately9500fwhmwas
used for determination of elemental composition with TOF
mass spectrometer. MS and MS/MS spectra were acquired in
centroid mode over an m/z range of 50–1000 in scan time
1s and inter scan time 0.1s. The detector potential was set
to 1850V. Reproducible and accurate mass measurements at
approximate 10000 mass resolution were obtained using an
electrospraydualsprayerwithleucineenkephalin([MH]
+ =
556.2771) as a reference compound, introduced into the
mass spectrometer alternating with a sample solution.
The data station operating software was Mass Lynx v. 4.1
(Micromass, Manchester).
Interpretation ofpeaksinmassspectraandidentiﬁcation
of particular fragment ions were conﬁrmed with elemental
composition mass measurements of these ions at high
resolution.
2.1.3. CHN Elemental Analysis. Elemental analyses were
performedonaPerkin-ElmerElementalanalyzer2400CHN.
2.1.4. X-Ray Structure Analysis. X-ray diﬀraction data were
collected on a Nonius Kappa CCD diﬀractometer at 150K
for compound 1a and at room temperature for compound
1b using graphite monochromated Mo-Kα radiation and
processed using DENZO [14] program. The structures
were solved using SIR92 [15]. A full-matrix least-squares
reﬁnement on F magnitudes with anisotropic displacement
factors for all nonhydrogen atoms using SHELXL [16]w a s
employed. The drawings were prepared with the Mercury
program [17]. Hydrogen atoms were placed in geometrically
calculated positions and were reﬁned using a riding model.
The crystallographic data for compounds 1aand1b have
been deposited with the CCDC as supplementary material
with the deposition numbers CCDC 759890 and 759818,
respectively (see Supplementary Material available online at
doi:10.1155/2010/183097).
2.2. Syntheses. Syntheses of [RuCl4(dmso-S)(histamine-
H)]·H2O (1a) and [RuCl4(dmso-S)(histamineH)] (1b): the
synthesis of compounds 1a and 1b consists of two steps
(see Scheme 3). The ﬁrst step is the preparation of a
ruthenium precursor P1 (dmso2H)[trans-RuCl4(dmso-S)2].
This compound was prepared according to the literature
[18]. 200mg of P1 and 70mg of histamine dihydrochloride
were dissolved in 15mL of methanol and reﬂuxed for 4
hours. After a slow evaporation of the solvent, only a few
red crystals of 1a were obtained. The X-ray structureanalysis
showed the presence of a solvate water in a molecule.
Despite considerable eﬀort, we were not able to obtain such
crystals again. Crystals of compound 1b were later obtained
by adding 15mL of ethanol to the reaction mixture and
the solution was left to stand in an open ﬂask. Overnight
snowﬂake-like crystalline orange solid formed. The crystals
were washed with cold acetone and diethylether and dried
at 50
◦C for 30 minutes. Similar crystals although of lower
qualitywereobtainedbyadditionofisopropanol,n-pentanol
or ethyl acetate, instead of ethanol, to the reaction mixture.
IR (ATR): 3226 (sh), 3115 (s), 2923 (w), 1597 (w), 1578
(w),1504(sh),1480(m),1402(m),1231(w),1111(sh),1082
(s), 1016 (s), 968 (s), 934 (s), 928 (sh), 840 (s), 684 (w), 658
(m) cm−1.
CHN (only 1b): Calc. C 19,41%, H 3,72%, N 9,70%;
Found: C 19,78%, H 3,67%, N 9,49%.
ESI-MS (in H2O solution): m/z 361, 325, 299, 264.
2.3. Biological Activity Assays. Murine melanoma cell line
B16F1(EuropeanCollectionofCellCultures,UK)wastested
in vitro to determine cytotoxic eﬀect of compound 1b in
combination with or without electroporation. B16F1 cell
suspension (22·106 cells/mL) was prepared in low conduc-
tive electroporation buﬀer (10mM (Na2HPO4/NaH2PO4,
pH 7.4) with 1mM MgCl2 and 250mM sucrose). Diﬀer-
ent concentrations of compound 1b were added to cell
suspension to reach ﬁnal concentrations of 0.01, 0.1, and
1mM. Immediately after incubation (<0.5min), a drop of
cellsuspensionwasplacedbetween twoﬂatparallelstainless-
steel electrodes 2mm apart and a train of electric pulses
(8 pulses, 800V/cm, 100μs, 1Hz) was applied with an
electroporator Cliniporator (Igea, Carpi, Italy). The same
procedure without electric pulses was used for cells exposed
to diﬀerent concentrations of 1b without electroporation.4 Bioinorganic Chemistry and Applications
O a
b
Figure 3: The packing in the crystal structure of compound 1a along the z axis.
Table 1: Crystal data and structure reﬁnement for compounds 1a and 1b.
Compound 1a Compound 1b
Empirical formula C7H16Cl4N3O2RuS C7H16Cl4N3ORuS
Formula weight 449.16g/mol 433.16g/mol
Temperature 150(2)K 293(2)K
Wavelength 0.71073 ˚ A 0.71073 ˚ A
Crystal system Triclinic Monoclinic
Space group P3 121 C2/c
Unit cell dimensions a = 8.233 ˚ A a = 14.4860(8) ˚ A
b = 8.233 ˚ A b = 7.8741(3) ˚ A
c = 38.9269(3) ˚ A c = 27.3464(15) ˚ A
α = 90
◦ α = 90
◦
β = 90
◦ β = 91.457(2)
◦
γ = 120
◦ γ = 90
◦
Volume 2284.943(18) ˚ A
3 3118.2(3) ˚ A
3
Z 68
Density (calculated) 1.959g/cm3 1.845g/cm3
Absorption coeﬃcient 1.864mm−1 1.813mm−1
F(000) 1338 1720
Crystal size 0.1 × 0.1 × 0.1mm 0.08 × 0.05 × 0.05mm
Theta range for data collection 3.26 to 28.71
◦ 3.22 to 27.49
◦
Reﬂections collected 7263 5747
Independent reﬂections 3830 [R(int) = 0.0166] 3501 [R(int ) = 0.0290]
Reﬁnement method Full-matrix least-squares on F2 Full-matrix least-squares on F2
Data/restraints/parameters 3830/0/166 3501/0/172
Goodness-of-ﬁt on F 2 1.068 1.080
Final R indices [I >2sigma(I)] Ra
1 = 0.0236, wRb
2 = 0.0571 R1 = 0.0500,wR2 = 0.1120
R indices (all data) R1 = 0.0261, wR2 = 0.0583 R1 = 0.0761,wR2 = 0.1229
Largest diﬀ. peak and hole 1.229 and −0.686 e·˚ A
3 1.098 and −0.560 e·˚ A
−3
aR1 =

(|Fo|−|Fc|)/

|Fo|; bwR2 ={ [w(F2
o −F2
c )
2]/

[wF2
o]}
1/2
In addition, we tested cytotoxic eﬀect of 1b after prolonged
incubation time (60min, without electroporation). Cell
viability was measured 72h after treatment using the MTS-
based Cell Titer 96 AQueous One Solution Cell Proliferation
Assay (Promega, Madison, WI, USA). Absorption at 490nm
wavelength (A490) was measured with a spectrophotometer
Tecan inﬁnite M200 (Tecan, Switzerland). Cell viability
(C.V.) of treated cells (tr) was calculated using the formula:
C.V. = (A490)tr/(A490)c × 100[%], taking the cell viability
of the control I as 100%. Statistical analysis was performedBioinorganic Chemistry and Applications 5
using One-Way ANOVA test and SigmaStat statistical soft-
ware (SPSS, Chicago, USA).
3. Results andDiscussion
3.1. Synthesis and Crystal Structure. Several complexes of the
NAMI and KP families bearing nitrogen-bound simple hete-
rocycles or smaller biologically active molecules were already
synthesized and investigated for biological applications [4,
7, 19, 20]. Most of the NAMI analogues were synthesized
by mixing a suspension of P1 in acetone and adding the
equivalent amount of the ligand and then recrystallizing
the product either from hot acetone or other solvents. In
our case this synthetic route was not appropriate due to
the low solubility of compound 1b in acetone or other
solventsexceptinwaterandmethanol.Thereactionwasthus
performed in methanol and another less volatile and less
polar solvent was added later. Similar crystals although of
lower quality were obtained by addition of isopropanol, n-
pentanol, or ethyl acetate instead of ethanol to the reaction
mixture. The crystals were cut and were suitable for X-
ray structure analysis. The experimental data is shown in
Table 1.
The asymmetric unit of compound 1b is shown in
Figure 1. Selected bond lengths and hydrogen bond short
contactdistancesarepresentedinTables2and3,respectiv ely .
The crystal structure of compounds 1a and 1b does
not diﬀer signiﬁcantly from the other NAMI-type com-
pounds. Compounds 1a and 1b have a distorted octahedral
geometry with four in-plane chloride anions surrounding
the Ru(III) ion in addition to a sulfur atom from an S-
bonded dimethylsulfoxide molecule and a nitrogen atom
from the histamine molecule in axial positions. The main
diﬀerence to most of the NAMI-type compounds which
are anionic complexes is the protonated amino group on
the side chain of the histamine moiety (hence histamineH
is used in the formula) that gives compounds 1a and 1b
a neutral charge. This structural feature is however more
commonin NAMI-type compounds with a purine derivative
as the nitrogen ligand [21]. The hydrogen atoms on the
amino group (H3A, H3B and H3C) form hydrogen bonds
with the four chloride atoms and the dmso oxygen. The
Cl2 chloride atom forms an additional hydrogen bond
with the hydrogen on the imidazole moiety (H2) which
results in a slightly longer Ru-Cl2 distance (see Tables 2
and 3 and Figures 1 and 2). Compound 1a exhibits an
additional hydrogen bond between the water molecule and
one of the chloride anions. It was not possible to locate
the positions of two hydrogen atoms bonded to oxygen in
a water molecule of the complex 1a by diﬀerence Fourier
maps.
Another interesting feature of the crystal structure of
compound 1aistheformationofchannelsalongz axiswhere
the water molecules are located (see Figure 3).
3.2. Electrospray Ionization Mass Spectrometry. Compound
1b was also characterized by electrospray ionization mass
spectrometry. The peaks in the mass spectrum and their
Table 2: Selected bond lengths in compounds 1a, 1b and NAMI
[22](Na[RuCl4(S-dmso)(imidazole)]).
1a 1b NAMI
Ru–Cl1 2.355 (2) 2.359 (2) 2.3403 (9)
Ru–Cl2 2.364 (2) 2.364 (2) 2.3227 (8)
Ru–Cl3 2.356 (2) 2.343 (2) 2.3588 (9)
Ru–Cl4 2.358 (2) 2.356 (2) 2.3447 (8)
Ru–S 2.300 (2) 2.298 (2) 2.2956 (6)
Ru–N 2.096 (2) 2.097 (2) 2.081 (2)
Table 3: Selected hydrogen bond short contact distances in
compound 1b.
D–H···AD – A ( ˚ A) angle DHA (◦)
N2–H2 ···Cl2 3.218 (6) 151
N3–H3A···Cl2 3.331 (6) 138
N3–H3A···Cl4 3.306 (6) 140
N3–H3B···Cl1 3.308 (6) 149
N3–H3B···Cl3 3.349 (6) 131
N3–H3C···O1 2.889 (6) 172
Table 4: Main peaks in the ESI-MS spectrum of compound 1b and
respective assignments.
m/z fragment
264 RuCl(histamine)(OH)
299 RuCl2(histamine)(OH)
325 RuCl(dmso)(histamine)
361 RuCl2(dmso)(histamine)
respective assignments are presented in Table 4. The data
conﬁrm a partial hydrolysis of the compound in water solu-
tion. Such behavior is usual for the NAMI-type compounds
which undergo a rather quick dissociation of two of the
chloride ligands and/or the dmso molecule [23].
3.3. Biological Activity. Previous studies have shown that
while NAMI-A is inactive against B16F1 cells in vitro,i t
shows remarkable activity at relatively low concentrations
when combined with electroporation [24]. On the other
hand compound 1b shows no activity at any of the tested
concentrations (up to 1mM) either by itself or in combina-
tion with electroporation.
As Dyson and Sava suggest [25], the cytotoxicity of a
compound as one of the main criteria in the preliminary
screenings when looking for a potential drug candidate
should be considered with some caution. NAMI-A for exam-
ple, showed remarkable antimetastatic properties despite
very low cytotoxicity. Further investigations of the biological
activity of the histaminic analogue and the study of the
interactions with diﬀerent proteins are being planned.6 Bioinorganic Chemistry and Applications
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